{"brief_title": "Pegvisomant And Sandostatin LAR Combination Study", "brief_summary": "The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.", "condition": "Acromegaly", "intervention_type": "Drug", "intervention_name": "Pegvisomant", "criteria": "Inclusion Criteria: - Diagnosis of acromegaly - Received previous radiation and/or surgical treatment for their GH (Growth Hormone) producing pituitary adenoma and have required medical therapy due to failure to normalize GH (Growth Hormone) and/or IGF-I as a result of their primary treatment - Patients that been receiving Sandostatin LAR for a minimum of 6 months prior to enrollment Exclusion Criteria: - Presence of other conditions that may result in abnormal GH (Growth Hormone) and/or IGF-I concentrations - Patients on current medical therapy other than Sandostatin LAR - AST/ALT >= 3xULN (upper limits of normal) - Pituitary adenoma within 3mm of optic chiasm confirmed by recent MRI - Visual field defects (except post-surgical stable residual defects) - Unable to self administer drug - Radiotherapy within 12 months of entering the study", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00068029.xml"}